Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities

 
• By Emily Hayes
  
BMY Chief Scientific Officer Thomas Lynch
Bristol's Chief Scientific Officer Thomas Lynch • Source: Bristol-Myers Squibb
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer